
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion has demonstrated a robust growth trajectory through its deepening partnership with Merck, which not only enhances its credibility but also provides financial backing for future innovations. The company has effectively built a versatile AI-Immunology platform that has resulted in a strong portfolio of preclinical and clinical candidates, positioning it for significant milestones in the near future. Additionally, recent fundraising efforts have improved its financial stability, further bolstering Evaxion's capacity to expand its vaccine pipeline and drive value creation in both the oncology and infectious disease sectors.
Bears say
Evaxion AS is positioned in the oncology sector with an AI-Immunology platform; however, its focus on ERV-targeting in tumors with low mutation burden presents a significant risk due to limited efficacy outcomes historically associated with this approach. The company's ability to deliver successful treatments in this challenging segment remains uncertain, raising concerns regarding its long-term financial viability and growth potential. Additionally, the historical performance of checkpoint inhibitors and neoantigen vaccines in such tumors may further jeopardize investor confidence and future revenue generation.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares